Overview
Be sure to attend the 31st Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas, and Myeloma, which will make a difference in improving care for your patients. This engaging and highly interactive meeting will provide ample opportunity for you to interact with internationally renowned experts in the management of leukemias, lymphomas, myeloma, myelodysplastic syndromes, and myeloproliferative neoplasms.
We have added several case-based panel discussions that will allow you to see how experts navigate the decision-making process and integrate the latest clinical trial data. This program will continue to spotlight the expanding array of new therapies for patients with hematologic malignancies, including T cell–based therapy, targeted therapy, and antibody-drug conjugates. Our faculty will distill practice-changing evidence and recommend ways to put this information into clinical context so that you can apply the latest evidence to real-world patient care scenarios. Proactive measures to mitigate and manage treatment-related toxicities associated with new and established therapies will also be discussed.
We are also excited to feature keynote lectures on how artificial intelligence–based techniques can improve patient care and how more-sensitive measurable residual disease techniques may move the field of myeloma toward increasing survival while decreasing the adverse events of treatment.
We look forward to seeing you in Miami Beach for an exciting International
Congress on Hematologic Malignancies!